Heles and colleagues (2026) gave mice as few as two doses of psilocybin before chemotherapy and prevented signs of nerve damage through repeated treatment cycles. The drug protected touch sensation and nerve endings without reducing chemotherapy’s action against tumors in the tested models.
The result addresses a hard problem in cancer care. Chemotherapy-induced peripheral neuropathy, or CIPN, can cause pain, numbness and extreme sensitivity to cold. Current evidence does not yet show that psilocybin prevents CIPN in people. A Phase 2 trial will now test that question.
What the new psilocybin study found
The research did not test cancer patients
The study in Science used mice and lab models rather than completed human treatment data. The team tested three chemotherapy drugs linked to nerve damage. They were cisplatin, paclitaxel and docetaxel.
Heles and colleagues (2026) reported that psilocybin prevented the onset of neuropathy in platinum-based and taxane-based models. The protection continued across repeated chemotherapy cycles. Tests also showed that psilocybin did not weaken the cancer-fighting effect of chemotherapy in those models.
That last result answers one safety concern at the preclinical stage. A compound that shields nerves would have little medical use if it also shielded tumors. The mouse data did not show that problem, but human trials must test safety and benefit in patients.
Two early doses protected sensation
According to MD Anderson’s study report, as few as two psilocybin doses given before chemotherapy prevented cold hypersensitivity. The treatment also preserved touch sensation and the tiny sensory nerve endings that reach the skin.
The timing separates this work from studies that treat pain after nerve injury has started. Psilocybin acted as a preventive treatment in the models. It was present before chemotherapy placed the nerves under stress.
Why chemotherapy can damage nerves
Tingling can progress to lost sensation
Peripheral nerves carry touch, pain and temperature signals between the body and the brain. Some chemotherapy drugs injure the long sensory fibers that reach the hands and feet. A patient can feel tingling, burning pain, numbness or pain from cold objects that would not normally hurt.
These symptoms can disturb sleep, walking and fine hand movements. Numb feet can affect balance. Numb fingers can make buttons, cooking tools and phone screens harder to use. The effects show how toxic exposure can affect the nervous system, while pain from damaged sensory fibers offers another way to understand how pain begins in the nervous system.
Neuropathy can last after chemotherapy ends
Seretny and colleagues (2014) combined data from 31 studies. They found CIPN in 68.1% of patients during the first month after chemotherapy, 60.0% at three months and 30.0% at six months or later. The figures varied by drug and patient risk, but they show that nerve symptoms can continue well after treatment.
Severe neuropathy can also force a doctor to delay chemotherapy, lower the dose or stop a drug. That creates a painful tradeoff between protecting daily function and delivering the planned cancer treatment.
Related. More from our health reporting.
How psilocybin protected sensory nerves
A serotonin receptor outside the brain took part
Psilocybin is best known for its effects in the brain. The new study also traced its nerve protection to 5-HT2A serotonin receptors in the peripheral nervous system.
When the researchers blocked 5-HT2A signaling, the protection disappeared. A non-hallucinogenic compound that activated the same receptor produced similar nerve protection. Those tests suggest that the effect did not require the altered perception linked to a psychedelic experience.
The result also gives researchers a more exact target. Future work can test whether drugs that act on peripheral 5-HT2A receptors protect nerves with fewer effects on perception.
Nerve endings need moving mitochondria
Mitochondria produce usable energy inside cells. Nerve fibers must move these structures along axons, the long extensions that carry signals. Nerve endings can lose power when that transport system fails.
Heles and colleagues (2026) found that cisplatin reduced both the number and movement of mitochondria inside nerve fibers. Psilocybin preserved that movement through a chain of cell signals called the TrkB-Akt-PAK5-MAP2-KIF5B pathway. The treatment also released mitochondria held in place by a protein called syntaphilin.
With energy supplies moving again, nerve endings kept their structure and touch function in the preclinical models. The study points to nerve energy transport as a possible way to prevent injury before symptoms begin.
What patients should know now
Mouse protection is not proof of human benefit
No completed trial has shown that psilocybin prevents chemotherapy neuropathy in people. Animal results often change when researchers test a treatment in patients. Dose, timing, other medicines and the type of cancer can all affect the result.
The gap between lab evidence and patient benefit is the same reason early human testing of regenerative medicine needs careful design. It also shows how early treatment claims should be weighed before doctors change care.
NeuroGuard will test three cancer groups
The NeuroGuard trial, listed as NCT07227909, is a randomized Phase 2 study with an estimated enrollment of 83 adults. It will include people with breast, colorectal or head and neck cancer who are scheduled to receive platinum chemotherapy or taxanes. As of the registry update in August 2026, the study had not yet started recruitment.
One group will receive four supervised 25-milligram oral doses, with two before the first chemotherapy cycle and two during later cycles. A second group will receive repeated 1-milligram subperceptual doses. A third group will receive standard care without a study drug.
The trial will track safety and changes in sensory symptoms. It will also examine whether neuropathy leads to chemotherapy dose changes.
Self-treatment carries medical risks
The study design does not support taking psilocybin without medical supervision. Trial staff screen participants for heart, liver and mental health risks. The protocol also restricts several medicines and requires monitoring, transport home and no driving after a supervised dose.
Cancer patients often take drugs for nausea, pain, mood and other symptoms. Some can conflict with a psilocybin protocol. Products sold outside research settings can also contain uncertain doses or different substances. Anyone concerned about neuropathy should speak with the oncology team and ask about registered trials rather than self-treat.
Why prevention could change cancer care
Doctors have no recommended preventive drug
Loprinzi and colleagues (2020) reviewed the evidence for an American Society of Clinical Oncology guideline. The panel found no drug it could recommend to prevent CIPN. It advised against acetyl-L-carnitine for prevention.
For painful neuropathy that already exists, duloxetine is the only drug with enough evidence for guideline support. Its benefit is limited. Doctors may also adjust chemotherapy when nerve problems become intolerable or impair function.
Prevention would address the injury before pain, numbness and lost sensation become established. That timing is useful because nerve damage can persist for years, alongside other long-term changes in adult brain health.
The human trial will test the central claim
NeuroGuard is designed to test whether preventive psilocybin lowers the rate or severity of sensory neuropathy during chemotherapy. It will also record treatment adherence and dose changes.
The mouse study supplies a mechanism and a reason to run that trial. The patient data will decide whether the protection survives the move from controlled models to cancer care.
References
Heles, M., Pasvolsky, L., Sathishkumar, H., et al. (2026). Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science, 393(6815), eaec6116. https://doi.org/10.1126/science.aec6116
Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Lavoie Smith, E. M., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. Journal of Clinical Oncology, 38(28), 3325-3348. https://doi.org/10.1200/JCO.20.01399
Mogensen, J. F. (2026, September 3). ‘Unparalleled’ study finds psilocybin protects against nerve damage from chemotherapy. Scientific American. https://www.scientificamerican.com/article/unparalleled-study-finds-psilocybin-protects-against-nerve-damage-from-chemotherapy/
National Library of Medicine. (2026). NeuroGuard: Psilocybin trial for preventing chemo-induced neuropathy (NCT07227909). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07227909
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014). Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain, 155(12), 2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
The University of Texas MD Anderson Cancer Center. (2026). Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models. https://www.mdanderson.org/newsroom/research-newsroom/psilocybin-prevents-chemotherapy-related-nerve-injury-and-associated-symptoms-in-preclinical-models.h00-159858501.html
